"rationale","name","uuid:ID","description","label","id","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","37b10855-b91d-4b86-955c-7b2d9da99c93","The main design for the study","","StudyDesign_1","StudyDesign"
